For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  ACE-031
Performance & Muscleearly_human

ACE-031

Ramatercept
Performance & Muscle
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Performance & Muscle
Evidence grade
C
PubMed records
48
Female-tagged
11
Sex-analysis
0
CAS
—
C
Evidence grade C, Early human data only (Phase 1 / small-n) across 48 indexed studies. How grades work →
Female evidence: Extrapolated
ACE-031: of 48 PubMed records, 11 are tagged as including female subjects and 0 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

ACE-031 is a recombinant fusion protein built from a soluble form of the activin receptor type IIB (ActRIIB) linked to a human IgG1 Fc domain. Engineered to act as a decoy receptor, it binds myostatin and related transforming-growth-factor-beta family ligands before they can reach cell-surface receptors, which gives it a defined mechanism as a research tool.

In preclinical models ACE-031 has been studied for its relationship to the myostatin signaling axis and the regulatory pathways that govern skeletal-muscle mass. Researchers examining activin and myostatin biology have used it as a research material to characterize how ligand sequestration alters these signaling cascades in cell-based and animal systems.

What makes ACE-031 a useful entry for a muscle-regulation research catalog is the clarity of its designed target, the ActRIIB ligand pathway. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

ACE-031 (ramatercept) is a soluble activin receptor type IIB–Fc fusion designed to inhibit myostatin signaling and increase muscle mass. It reached early human trials, including for Duchenne muscular dystrophy, but development was discontinued after vascular side effects, and no female-specific efficacy data were established.

Evidence in women

Menstrual cycle
Unstudied
No study examined muscle or vascular endpoints across the menstrual cycle.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data exist.
Hormonal interactions
Unstudied
No data on reproductive- or thyroid-hormone interactions.
Perimenopause & menopause
Unstudied
No perimenopause- or menopause-specific muscle or bone outcomes reported for this compound.
Sex differences
Unstudied
Trials enrolled some women, but results were not analyzed by sex before the program ended.

Mechanism

A decoy receptor (ActRIIB-Fc) that binds myostatin and related ligands, blocking activin-receptor signaling that normally restrains muscle growth.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Subcutaneous dosing was studied in early trials before the program was discontinued; not an established dose.
Routessubcutaneous
Female-specific dosingNot established

Contraindications: bleeding or vascular disorders (development halted for epistaxis and telangiectasia)

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

nosebleeds (epistaxis)dilated skin blood vessels (telangiectasia)gum bleeding

ACE-031 reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for ACE-031

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from ACE-031's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is ACE-031?

ACE-031, also known as Ramatercept, is a research compound in our performance muscle category. ACE-031 (ramatercept) is a soluble activin receptor type IIB–Fc fusion designed to inhibit myostatin signaling and increase muscle mass.

Is ACE-031 studied in women?

ACE-031: of 48 PubMed records, 11 are tagged as including female subjects and 0 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has ACE-031 been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data exist. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does ACE-031 have, and why?

ACE-031 carries evidence grade C. Early human data only (Phase 1 / small-n) across 48 indexed studies.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for ACE-031?

No. A female-specific dose for ACE-031 is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is ACE-031 administered in research?

In the published literature, ACE-031 is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for ACE-031?

Effects reported in the research literature include nosebleeds (epistaxis), dilated skin blood vessels (telangiectasia), gum bleeding. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should ACE-031 be stored and handled?

ACE-031 sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy ACE-031 for research?

For laboratory research use, ACE-031 is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy ACE-031 at Aurevena Research
Research-use supplier: ACE-031 is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Citations (PMID)

29109273 · 40312924

Related peptides

2X Blend CJC-1295 WO DAC (5mg) / Ipamorelin·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
AICARB
AICAR: of 2,496 PubMed records, 329 are tagged as including female subjects and 2 carry a sex-analysis tag.
CJC-1295 with DACC
CJC-1295 with DAC: of 32 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.
CJC-1295 Without DACD
CJC-1295 Without DAC: of 5 PubMed records, 1 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.